Intellipharmaceutics International Inc. Share Price OTC Markets

IPCIQ

CA4581733090

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 14:36:26 24/07/2026 BST			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	-

Valuation: Intellipharmaceutics International Inc.

Market Cap	1.28M 1.13M 1.05M 960K 1.8M 123M 1.83M 12.43M 4.86M 60.66M 4.81M 4.71M 210M	P/E 2021	-0.4x	P/E 2022	-0.91x
Enterprise Value	3.52M 3.09M 2.88M 2.64M 4.96M 339M 5.04M 34.18M 13.35M 167M 13.23M 12.94M 577M	EV / Sales 2021	-	EV / Sales 2022	74x
Free-Float	98.24%	Yield 2021 *	-	Yield 2022	-

* Estimated data More valuation ratios

Chart: Intellipharmaceutics International Inc.

Dynamic Chart

Managers and Directors: Intellipharmaceutics International Inc.

Manager	Title	Age	Since
Amina Odidi DFI	Director of Finance/CFO	-	-
Fazayill Shaideen AUD	Comptroller/Controller/Auditor	-	31/03/2007
Christian Akyempon PRN	Corporate Officer/Principal	-	31/01/2014

Director	Title	Age	Since
Amina Odidi BRD	Director/Board Member	-	31/08/2004

More insiders

Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a range of existing and new pharmaceuticals. It has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development. The Company has ANDA and NDA 505(b)(2) drug product candidates in its development pipeline. These include the Companyâ€™s abuse-deterrent oxycodone hydrochloride extended-release formulation (Oxycodone ER) based on its proprietary nPODDDS novel Point of Divergence Drug Delivery System (for which an NDA has been filed with the FDA), and Regabatin XR (pregabalin extended-release capsules). Its product portfolio includes both new products and controlled-release generic products.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume

Delayed Quote OTC Markets

More quotes

As early as today, start finding the best investment opportunities!

3 years	0		0.15
5 years	0		0.3
10 years	0		33.5

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INTELLIPHARMACEUTICS INTERNATIONAL INC.	0.00%	0.00%	-	-	1.52M
ELI LILLY AND COMPANY	+0.86%	+1.43%	+48.50%	+160.39%	1,057B
JOHNSON & JOHNSON	+1.59%	+4.09%	+55.34%	+53.96%	624B
ABBVIE INC.	+0.95%	+1.91%	+35.91%	+81.14%	454B
ROCHE HOLDING AG	+1.60%	+6.25%	+33.95%	+29.84%	341B
NOVARTIS AG	-0.60%	+1.52%	+35.68%	+39.76%	297B
ASTRAZENECA PLC	-0.14%	+0.60%	+16.17%	+17.53%	262B
NOVO NORDISK A/S	+0.09%	-2.82%	-28.29%	-41.71%	215B
AMGEN INC.	+1.22%	+2.66%	+21.87%	+59.73%	201B
GILEAD SCIENCES, INC.	-1.18%	-3.70%	+14.23%	+66.51%	162B
Average	+0.33%	+1.26%	+25.93%	+51.91%	401.55B
Weighted average by Cap.	+0.54%	+1.92%	+35.73%	+77.61%

	2021	2022
Net sales	-	65.73K 57.73K 53.69K 49.26K 92.56K 6.33M 93.99K 638K 249K 3.11M 247K 241K 10.76M
Net income	-5.15M -4.52M -4.2M -3.86M -7.25M -495M -7.36M -49.9M -19.5M -244M -19.31M -18.9M -842M	-2.89M -2.54M -2.36M -2.17M -4.07M -279M -4.14M -28.05M -10.96M -137M -10.86M -10.62M -473M
Net Debt	1.15M 1.01M 936K 859K 1.61M 110M 1.64M 11.11M 4.34M 54.23M 4.3M 4.21M 188M	2.24M 1.97M 1.83M 1.68M 3.16M 216M 3.21M 21.75M 8.5M 106M 8.42M 8.24M 367M

Intellipharmaceutics International Inc. Share Price OTC Markets

Stocks

IPCIQ

CA4581733090

Pharmaceuticals

Valuation: Intellipharmaceutics International Inc.

Chart: Intellipharmaceutics International Inc.

Course Extremes

Managers and Directors: Intellipharmaceutics International Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes